Is the Therapeutic Index Better with Gemcitabine-Based Chemoradiation

Ryan Smith, MD
University of Pennsylvania Cancer Center
Ultima Vez Modificado: 5 de noviembre del 2001

Presenter: Christopher Crane
Affiliation: M.D. Anderson Cancer Center
Type of Session: Scientific

Background

  • Locally advanced pancreatic cancer is both radioresistant and chemoresistant.
  • "Traditional" treatment with concurrent 5-FU chemoradiation results in a median survival of 9-12 months
  • In metastatic/advanced disease, gemcitabine is modestly better than 5-FU
  • This study was designed to compare the efficacy and toxicity of gemcitabine based chemoradiation with that of 5-FU based chemotherapy (the standard treatment)

    Materials and Methods

  • This is a retrospective look at 114 patients with localized, unresectable (but nonmetastatic) adenocarcinoma of the pancreas that were treated with either gemcitabine or 5-FU based chemoradiation
  • Unresectability was defined as celiac or SMA involvement or occlusion of the SMV-portal venous confluence
  • 53 pts. in the gemcitabine arm received concurrent XRT (30 Gy in 10 fractions)
  • 61 pts. in the 5-FU arm received concurrent XRT (30 Gy in 10 fractions)
  • Radiation was delivered to the primary tumor and regional nodes
  • Groups fairly balanced except: Gemcitabine patients were younger (60 vs 68 yrs), gemcitabine patients had a larger tumor cross sectional area (8.8 vs 5.7 cm2)

    Results

  • Gemcitabine patients developed significantly more severe toxicities during treatment (23% vs. 2%)
  • OS 11 months (gemcitabine) vs 9 months (5-FU), with 1 yr OS rate 42% vs 28%
  • Local progression rate 73% (gemcitabine) vs. 61% (5-FU)
  • 5/53 had eventual resection in the gemcitabine group. 4/5 had <1 cm of abutment of the SMA and 1/5 likely had an original component of pancreatitis

    Author's Conclusions

  • Despite selection bias (younger, healthier patients), significantly higher severe toxicity with the gemcitabine group
  • No statistically significant improvement in 1 yr OS, local progression
  • 5/53 had resection in the gemcitabine group, even though these patients had, on average, larger tumors prior to therapy
  • Most important factor for the development of toxicity is the amount of mucosa irradiated

    Clinical/Scientific Implications
    In patients with locally advanced pancreatic cancer, cure is often not feasible. Therefore, different endpoints (palliation, extension of life) are used. Given these facts, excessive morbidity from treatment should be avoided if possible. This study resulted in a 23% rate severe toxicity in the gemcitabine arm plus radiation therapy arm. This was seen without much improvement in OS or local control. Although some patients were able to undergo resection, the patient characteristics or outcomes after surgery were not revealed. Therefore, although the use of gemcitabine is a possible encouraging step forward in pancreatic cancer, it should be used with caution, under close observation, and only on a study protocol.

    Oncolink's ASTRO Coverage made possible by an unrestricted Educational Grant from Bristol-Myers Squibb Oncology and Pharmacia Oncology.

  • Blogs

    Breaking news: Supreme Court votes to uphold Affordable Care Act Subsidies
    by Christina Bach, MSW, LCSW, OSW-C
    June 26, 2015

    Related News

    Promise for Erlotinib + Cisplatin Chemoradiation in Cervical CA

    Mar 11, 2014

    Complete response for 94.4 percent of women with locally advanced cervical cancer


    AACR: Melanoma Biomarker Predicts Drug Sensitivity

    Oct 25, 2013

    Biomarker can be monitored in real-time during treatment


    AACR: Genetic Data ID Breast Cancer Progression Pathways

    Sep 16, 2011

    Identification of pathways, driver genes leads to novel targeted therapy for breast cancer